The Data Management and Biostatistics Core (DMBC) will serve as a resource and collaborator for all projects and cores related to this program project. Specifically the DMBC will: (1) consult on the design of all projects and in the application of appropriate statistical and methodological techniques;(2) lead and collaborate in data analysis and report preparation for all cores and projects, especially in the analysis of associations among longitudinal growth/decline patterns of all disease markers across the individual projects;(3) coordinate and implement participant scheduling program across all projects and cores;(4) continue our collaboration with the WU Center for Biomedical Informatics (CBMI) to complete the transition to our bioinformatics platforms, make data collected by ACS cores and projects available to all ACS investigators, and insure the quality control of all analysis data sets for publications;(5) collaborate in the design of all forms to be used;(6) develop, apply, and implement statistical data analysis techniques appropriate for addressing the scientific aims of the program project.
The Data Management and Biostafistics Core (DMBC) provides design, analyses, and data management resources to support all the ACS projects and cores. The relevance of the DMBC is that ACS addresses crucial public health questions to identify the eariiest possible biomarker changes for Alzheimer's disease and dementia so that prevention and/or treatment can be started early.
|Gabel, Matthew; Gooblar, Jonathan; Roe, Catherine M et al. (2018) Political Ideology, Confidence in Science, and Participation in Alzheimer Disease Research Studies. Alzheimer Dis Assoc Disord 32:179-184|
|Roe, Catherine M; Babulal, Ganesh M; Mishra, Shruti et al. (2018) Tau and Amyloid Positron Emission Tomography Imaging Predict Driving Performance Among Older Adults with and without Preclinical Alzheimer's Disease. J Alzheimers Dis 61:509-513|
|Musiek, Erik S; Bhimasani, Meghana; Zangrilli, Margaret A et al. (2018) Circadian Rest-Activity Pattern Changes in Aging and Preclinical Alzheimer Disease. JAMA Neurol 75:582-590|
|Aschenbrenner, Andrew J; Gordon, Brian A; Benzinger, Tammie L S et al. (2018) Influence of tau PET, amyloid PET, and hippocampal volume on cognition in Alzheimer disease. Neurology 91:e859-e866|
|Day, Gregory S; Gordon, Brian A; Perrin, Richard J et al. (2018) In vivo [18F]-AV-1451 tau-PET imaging in sporadic Creutzfeldt-Jakob disease. Neurology 90:e896-e906|
|Lewczuk, Piotr; Riederer, Peter; O'Bryant, Sid E et al. (2018) Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: An update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry. World J Biol Psychiatry 19:244-328|
|Oxtoby, Neil P; Young, Alexandra L; Cash, David M et al. (2018) Data-driven models of dominantly-inherited Alzheimer's disease progression. Brain 141:1529-1544|
|Allison, Samantha; Babulal, Ganesh M; Stout, Sarah H et al. (2018) Alzheimer Disease Biomarkers and Driving in Clinically Normal Older Adults: Role of Spatial Navigation Abilities. Alzheimer Dis Assoc Disord 32:101-106|
|La Joie, Renaud; Bejanin, Alexandre; Fagan, Anne M et al. (2018) Associations between [18F]AV1451 tau PET and CSF measures of tau pathology in a clinical sample. Neurology 90:e282-e290|
|Broce, Iris; Karch, Celeste M; Wen, Natalie et al. (2018) Correction: Immune-related genetic enrichment in frontotemporal dementia: An analysis of genome-wide association studies. PLoS Med 15:e1002504|
Showing the most recent 10 out of 352 publications